Topic summary

Oral versus injected administration claims for BPC-157

Compounds › Repair & healing peptides BPC-157 observational data preprint TB-500 needs a source

This is a generated summary. It shows the 5 most-liked posts from a topic of 25, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

m.radichTL2 Moderator9 Mar 2026#4

ra.mensa, post #1: Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows. My reading is that the trial is sound for… Go to post

The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.

24 likes in reply to #1 5mo

j.ivaturiTL2 Moderator11 Mar 2026#8

a.adeyemi, post #2: Oral versus injected administration claims for BPC-157: the preclinical work studied injection. Oral claims are common in supplier marketing and poorly supported by published evidence. If you are comparing orality between compounds, that is a distinction worth noting. Go to post

What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.

17 likes in reply to #2 5mo

b.brandtTL2 Moderator13 Mar 2026#13

Stability of BPC-157 in solution: what has been measured in published work covers specific formulations under specific conditions. Extrapolating to a reconstituted preparation in a different diluent at a different concentration is an extrapolation, acknowledged as one.

20 likes 5mo

IbrahimoviTL2Member15 Mar 2026#18

Worth separating two things that post #14 runs together.

BPC-157: the preclinical literature is extensive, mostly from a small number of research groups, and reports effects across a wide range of injury models. The breadth of reported effects is itself worth noting — a compound that improves outcomes in tendon, muscle, gut, nerve and bone through a single mechanism would be remarkable, and remarkable claims deserve proportionate scrutiny.

29 likes 4mo

k.salinasTL2 Moderator15 Mar 2026#20

Coming back to post #18, because the follow-up matters more than the original answer.

Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.

19 likes 4mo

Read the full topic (25 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Publication patterns in the BPC-157 literature, examined Compounds › Repair & healing peptides preprint BPC-157 TB-500 needs a source Solved Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of…	+40	45	3.4k	21h
BPC-157: what the rodent literature actually shows, and what it does not Compounds › Repair & healing peptides observational data preprint BPC-157 needs a source BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a…	+44	48	3k	10mo
Why plausible mechanism is not evidence of effect — one year on Compounds › Repair & healing peptides needs a source preprint BPC-157 Solved Closed The question in the title: Why plausible mechanism is not evidence of effect — one year on I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read…	+3	7	3.6k	13mo
Reading a preclinical wound-healing model and its relevance to a human tendon Compounds › Repair & healing peptides TB-500 preprint observational data Wiki Closed On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support…	+149	160	3.3k	20mo
Stability of BPC-157 in solution: what has been measured — one year on Compounds › Repair & healing peptides needs a source observational data preprint BPC-157 On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. Comparing STEP 2 ( Lancet , 2021) with STEP 1 ( N Engl J Med , 2021)…	+84	98	7.8k	18h

Related topics — sharing the tags BPC-157, observational data, preprint

Topic	Participants	Replies	Views	Activity
A structured critique template this community uses Evidence › Study critique observational data effect size risk of bias A structured critique template this community uses — setting out what I have, and where I think it stops being reliable. Comparing SURMOUNT-2 ( Lancet , 2023) with SURPASS-4 ( Lancet , 2021) and finding the…		2	18k	1d
When "no data" is the complete and final answer Compounds › Other compounds custom synthesis mislabelling needs a source research use only Solved Asking directly, because I could not find a straight answer: When "no data" is the complete and final answer I have seen SURMOUNT-1 ( N Engl J Med , 2022) cited in support of a claim I do not think it…	+154	165	6.3k	15mo
Melanocortin agonists: mechanism and the documented adverse profile Compounds › Other compounds needs a source mislabelling research use only custom synthesis Melanocortin agonists: mechanism and the documented adverse profile — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURMOUNT-2 ( Lancet , 2023) and…	+7	11	5.5k	20mo
What TRIUMPH is designed to answer, and why we should not pre-empt it Compounds › Retatrutide retatrutide effect size TRIUMPH programme preprint Solved What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…	+4	8	142	6h
The retatrutide phase 2 obesity paper, read closely Compounds › Retatrutide preprint effect size TRIUMPH programme Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting;…		2	65k	10mo